Endogenous Targeting of Lipid Nanoparticles to Kidney Tumors
Source abstract
Abstract
Although the delivery of genetic therapies to tumors using nanoparticles remains challenging, targeting may be enabled via plasma membrane receptors overexpressed on certain cancer cells. Here, we developed an endogenous targeting strategy for trafficking intravenously administered mRNA (and siRNA) lipid nanoparticles (LNPs) to clear cell renal cell carcinoma (ccRCC) kidney tumors. LNPs were engineered to adsorb circulating plasma vitronectin (Vtn), the ligand for α V β 3 integrin/vitronectin receptor (Vtn-R), which is overexpressed in ccRCC. Functional mRNA delivery to human ccRCC cells was enhanced 952-fold in vitro and 42-fold in patient-derived ccRCC tumor fragments orthotopically transplanted in mice. This proof-of-concept study represents a new direction in the cancer nanomedicine field by modulating the physicochemical properties of LNPs to achieve in situ ligand binding and tumor targeting.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering, Program in Genetic Drug Engineering
The University of Texas Southwestern Medical Center
Department of Biochemistry, Simmons Comprehensive Cancer Center
Department of Internal Medicine/Hematology-Oncology
Kidney Cancer Program, Simmons Comprehensive Cancer Center
Department of Pathology
Funding
National Cancer Institute · Welch Foundation · National Institute of Biomedical Imaging and Bioengineering · Congressionally Directed Medical Research Programs
References (72)
Show source-provided references
1. 10.1038/s41571-023-00811-910.1038/s41571-023-00811-9 ↗
2. 10.1038/s41578-022-00529-710.1038/s41578-022-00529-7 ↗
3. 10.1016/j.addr.2024.11519010.1016/j.addr.2024.115190 ↗
4. 10.1038/nrd261410.1038/nrd2614 ↗
5. 10.1038/s41563-021-01047-710.1038/s41563-021-01047-7 ↗
6. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
7. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
8. 10.1016/j.jconrel.2014.03.05710.1016/j.jconrel.2014.03.057 ↗
9. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
10. 10.1016/j.jconrel.2022.03.04310.1016/j.jconrel.2022.03.043 ↗
11. 10.1016/j.jconrel.2022.06.03510.1016/j.jconrel.2022.06.035 ↗
12. 10.1021/acs.bioconjchem.6b0043710.1021/acs.bioconjchem.6b00437 ↗
13. 10.1016/j.addr.2008.08.00510.1016/j.addr.2008.08.005 ↗
14. 10.1016/j.jconrel.2014.12.03010.1016/j.jconrel.2014.12.030 ↗
15. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
16. 10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
17. 10.1016/j.nantod.2019.02.00510.1016/j.nantod.2019.02.005 ↗
18. 10.1016/j.addr.2012.09.03810.1016/j.addr.2012.09.038 ↗
19. 10.1186/s40169-017-0175-010.1186/s40169-017-0175-0 ↗
20. 10.1038/s41563-020-0755-z10.1038/s41563-020-0755-z ↗
21. 10.1038/s41568-022-00496-910.1038/s41568-022-00496-9 ↗
22. 10.1021/acs.bioconjchem.0c0036610.1021/acs.bioconjchem.0c00366 ↗
23. 10.1002/adma.20180574010.1002/adma.201805740 ↗
24. 10.2147/IJN.S12930010.2147/IJN.S129300 ↗
25. 10.1038/s41576-021-00439-410.1038/s41576-021-00439-4 ↗
26. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
27. 10.1038/s41591-022-02061-110.1038/s41591-022-02061-1 ↗
28. 10.1038/s41565-021-00898-010.1038/s41565-021-00898-0 ↗
29. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
30. 10.1016/j.addr.2020.06.02610.1016/j.addr.2020.06.026 ↗
31. 10.1038/mt.2010.8510.1038/mt.2010.85 ↗
32. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
33. 10.1126/science.adk942810.1126/science.adk9428 ↗
34. 10.1038/s41467-023-42948-210.1038/s41467-023-42948-2 ↗
35. 10.1016/j.jconrel.2023.07.05810.1016/j.jconrel.2023.07.058 ↗
36. 10.1002/anie.20231039510.1002/anie.202310395 ↗
37. 10.1002/adma.20231379110.1002/adma.202313791 ↗
38. 10.1038/s41565-024-01680-810.1038/s41565-024-01680-8 ↗
39. Wechsel H. W. · Anticancer Res. · 1999 · 19 · 1529
40. 10.1002/ijc.2826710.1002/ijc.28267 ↗
41. 10.1158/1078-0432.CCR-23-302910.1158/1078-0432.CCR-23-3029 ↗
42. 10.1158/1535-7163.MCT-17-047110.1158/1535-7163.MCT-17-0471 ↗
43. 10.1158/1078-0432.CCR-22-096310.1158/1078-0432.CCR-22-0963 ↗
44. 10.1016/S0049-3848(97)00298-310.1016/S0049-3848(97)00298-3 ↗
45. 10.1016/j.ccell.2019.01.00710.1016/j.ccell.2019.01.007 ↗
46. 10.1038/s41581-024-00906-110.1038/s41581-024-00906-1 ↗
47. 10.1021/mp300273310.1021/mp3002733 ↗
48. 10.1038/nrc274810.1038/nrc2748 ↗
49. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
50. 10.1038/nprot.2014.10810.1038/nprot.2014.108 ↗
51. 10.1038/s41596-022-00755-x10.1038/s41596-022-00755-x ↗
52. 10.1126/scitranslmed.300364310.1126/scitranslmed.3003643 ↗
53. 10.1016/j.celrep.2021.11005510.1016/j.celrep.2021.110055 ↗
54. 10.1158/0008-5472.CAN-13-106910.1158/0008-5472.CAN-13-1069 ↗
55. 10.1021/acs.nanolett.0c0059610.1021/acs.nanolett.0c00596 ↗
56. 10.1038/s41587-023-01679-x10.1038/s41587-023-01679-x ↗
57. 10.1021/jacs.2c1289310.1021/jacs.2c12893 ↗
58. 10.1093/nar/gkw11610.1093/nar/gkw116 ↗
59. 10.1073/pnas.051104510310.1073/pnas.0511045103 ↗
60. 10.1016/j.omtm.2024.10140210.1016/j.omtm.2024.101402 ↗
61. 10.1089/nat.2018.073410.1089/nat.2018.0734 ↗
62. 10.1186/s13045-022-01292-610.1186/s13045-022-01292-6 ↗
63. 10.1038/s41591-020-1093-z10.1038/s41591-020-1093-z ↗
64. 10.1038/sj.onc.120393810.1038/sj.onc.1203938 ↗
65. 10.1038/s41581-020-00359-210.1038/s41581-020-00359-2 ↗
66. 10.1038/nrc318310.1038/nrc3183 ↗
67. 10.1038/nature1979610.1038/nature19796 ↗
68. 10.1056/NEJMoa210342510.1056/NEJMoa2103425 ↗
69. 10.1016/S1470-2045(25)00099-310.1016/S1470-2045(25)00099-3 ↗
70. 10.1158/1078-0432.CCR-19-145910.1158/1078-0432.CCR-19-1459 ↗
71. 10.1073/pnas.152075611310.1073/pnas.1520756113 ↗
72. 10.1021/la104590k10.1021/la104590k ↗